RRx-001 is a minimally toxic NLRP3 inhibitor (15, 16) in Phase 3 for small cell lung cancer (SCLC) (17) that is associated with vascular normalization (18) properties as well as epigenetic inhibition and tumor associated macrophage repolarization through CD47 downregulation (19, 20). The gene discussed is CD47; the disease is small cell lung carcinoma.